Detalles de la búsqueda
1.
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
Circulation;
149(6): 450-462, 2024 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37952217
2.
Prediction of new-onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS.
Diabetes Obes Metab;
2024 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38584567
3.
Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.
J Am Soc Nephrol;
34(12): 1965-1975, 2023 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37876229
4.
The Effect of Weight Loss Through Lifestyle Interventions in Patients With Heart Failure With Preserved Ejection Fraction-A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Heart Lung Circ;
33(2): 197-208, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38320881
5.
Colchicine in Cardiovascular Disease: In-Depth Review.
Circulation;
145(1): 61-78, 2022 01 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34965168
6.
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
Circulation;
145(19): 1460-1470, 2022 05 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35394821
7.
Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes.
Kidney Int;
104(4): 828-839, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37543256
8.
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
Am J Kidney Dis;
82(1): 84-96.e1, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36889425
9.
The importance of targeting multiple risk markers in patients with type 2 diabetes: A post-hoc study from the CANVAS programme.
Diabetes Obes Metab;
25(6): 1638-1645, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36782264
10.
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials.
Diabetes Obes Metab;
25(8): 2331-2339, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37184050
11.
The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial.
Diabetes Obes Metab;
25(12): 3724-3735, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37671609
12.
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
Diabetes Obes Metab;
25(8): 2151-2162, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37161691
13.
Artificial Intelligence in Cardiology: An Australian Perspective.
Heart Lung Circ;
32(8): 894-904, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37507275
14.
Contemporary Chest Pain Evaluation: The Australian Case for Cardiac CT.
Heart Lung Circ;
32(3): 297-306, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36610819
15.
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
Circulation;
143(18): 1735-1749, 2021 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33554616
16.
Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
Lancet;
397(10279): 1085-1094, 2021 03 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33711294
17.
Protocol for a novel sodium and blood pressure reduction intervention targeting online grocery shoppers with hypertension - the SaltSwitch Online Grocery Shopping randomized trial.
Am Heart J;
252: 70-83, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35777455
18.
Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.
Cardiovasc Diabetol;
21(1): 194, 2022 09 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-36151557
19.
Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.
Diabetes Obes Metab;
24(10): 1950-1956, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35635326
20.
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial.
Diabetes Obes Metab;
24(6): 1072-1083, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35166429